Document is current
Any future updates will be listed below
-
Authors
Willard, Kristen
Novak, Špela
Lio, Peter A.
Luttmann, Mark
McCreary, Gretchen
Mustafa, Ghulam
Tal-Singer, Ruth https://orcid.org/0000-0002-5275-8062
-
Funding
Funding for this research was provided by:
Sanofi
GAAPP
- License Information
-
More Information
Article History
Received: 6 October 2025
Accepted: 27 October 2025
First Online: 8 November 2025
Declarations
:
: Ruth Tal-Singer is a retiree and shareholder of GSK and reports personal fees from AstraZeneca, Boehringer Ingelheim, ENA Respiratory, Roche, Vocalis Health, Teva, ImmunoMet, Renovion, Samay Health, GSK, Italy&Beyond, COPD Foundation, Global Skin, and the Global Allergy and Airways Patient Platform. Ghulam Mustafa has nothing to disclose. Peter A. Lio reports being on the speaker's bureau for AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L’Oreal, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, and Verrica; reports consulting/advisory boards for Alphyn Biologics, AbbVie, Almirall, Amyris, Apogee, Arcutis, ASLAN, Astria Therapeutics, Boston Skin Science, Bristol-Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosci, Dermavant, Eli Lilly, Galderma, Kenvue, LEO Pharma, Lipidor, L’Oreal, Merck, Micreos, MyOR Diagnostics, Pelthos Therapeutics, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharma, Theraplex, Thimble Health, UCB, Unilever, Verdant Scientific, Verrica, and Yobee Care; has stock options with Alphyn Labs, Codex Labs, Concerto Biosci, Soteri Skin, Stratum Biosciences, Thimble, Yobee Care, and Verdant Scientific; has a patent pending for a Theraplex product with royalties paid; and is a Board member and Scientific Advisory Committee Member emeritus of the National Eczema Association. Mark Luttmann is a retiree and shareholder of GSK and reports personal fees from the COPD Foundation. Kristen Willard, Špela Novak, and Gretchen McCreary declare no competing interests.
: Before beginning the survey, invited individuals provided their consent to participate. An institutional review board exemption for the survey was obtained from a US-based central IRB (BRANY, Lake Success, NY; IRB00010793; 24-65-1643) since the survey research team was based in the US. The IRB exemption was granted under category #2, as detailed in 45 CFR 46.104(d). The survey was performed in accordance with the Declaration of Helsinki.
